@article{ref1,
title="18-Vinyldeoxycorticosterone: a potent inhibitor of the bovine cytochrome P-450(11) beta",
journal="Bioorganic and medicinal chemistry",
year="1998",
author="Davioud, E. and Piffeteau, A. and Delorme, C. and Coustal, S. and Marquet, A.",
volume="6",
number="10",
pages="1781-1788",
abstract="18-Vinylprogesterone (18-VP) and 18-ethynylprogesterone (18-EP) have proved to be potent suicide inhibitors of P-450(11) beta, the last enzyme of aldosterone biosynthesis (Delorme, C.; Piffeteau, A.; Viger, A.; Marquet, A. Eur. J. Biochem. 1995, 232, 247; Delorme, C.; Piffeteau, A.; Sobrio, F.; Marquet, A. Eur. J. Biochem. 1997, 248, 252). This paper describes the synthesis of 18-vinyldeoxycorticosterone (18-VDOC), an analogue of deoxycorticosterone (DOC), the physiological substrate of the enzyme, and the evaluation of its reversible inhibiting properties for deoxycorticosterone and corticosterone oxidation by the bovine enzyme. 18-VDOC has been obtained by hydroxylation at C-21 of a 18-VP precursor. Its reversible Ki values are, respectively, 0.3 microM for the 11 beta-hydroxylation and 0.8 microM for the 18-hydroxylation. Hence, 18-VDOC is the strongest competitive inhibitor of bovine P-450(11) beta described so far, but in contrast with 18-VP, it does not inhibit more efficiently the 18-hydroxylation than the 11-hydroxylation.<p /><p>Language: en</p>",
language="en",
issn="0968-0896",
doi="10.1016/s0968-0896(98)00106-0",
url="http://dx.doi.org/10.1016/s0968-0896(98)00106-0"
}